Alberta PROMs & EQ-5D Research & Support Unit (APERSU): A Brief Introduction. Dr. Jeff Johnson January 30, 2016

Similar documents
Strategic Operational Research Plan February 13, Scientific Office Digestive Health Strategic Clinical Network

Varicose Veins Surgery Questionnaire

Has Consumer Directed Care improved the quality of life of older Australians? Professor Julie Ratcliffe School of Medicine Flinders University

AN ENVIRONMENTAL SCAN OF ACTIVE LIVING AND FALL PREVENTION PROGRAMS FOR OLDER ADULTS IN ALBERTA

ARTIC PC. Diagnosis & treatment study Diary. Version 1 ( )

PROPOSED WORK PROGRAMME FOR THE CLEARING-HOUSE MECHANISM IN SUPPORT OF THE STRATEGIC PLAN FOR BIODIVERSITY Note by the Executive Secretary

Your Health Survey. Forename: Surname: Renal Unit: Type of treatment: If HD, are you: Date of birth: Home Post Code: Date completed: NHS number:

STRATEGIC DIRECTIONS AND FUTURE ACTIONS: Healthy Aging and Continuing Care in Alberta

Food for thought. Department of Health Services Research 1

Committee of Senior Representatives Tenth Meeting Oslo, Norway 11 December 2006

Research Initiatives and Future Plans

Ministry of Health and Long-Term Care. Palliative Care. Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW

Position No. Title Supervisor s Position Clinical Educator Executive Director Population Health

Cultural Diversity and Community Advisory Committee Charter

GOVERNMENT OF ALBERTA. Alberta s Plan for Pandemic Influenza

OUTLINE AAHPM & HPNA Annual Assembly DISCLOSURE. Dr. Hagen has no conflict of interest to report. Shaping public policy and enhancing care

Central East LHIN Self-Management Program

Improving Access to High Quality Hospice Palliative Care

pan-canadian Oncology Drug Review Initial Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer November 30, 2017

DEVELOPMENTS IN THE CLINICAL TRIALS ENVIRONMENT Two Initiatives February 27, 2014

Session 6: Choosing and using HRQoL measures vs Multi-Attribute Utility Instruments QLU-C10D and EQ-5D as examples

Health Aging Data Inventory Project

KAISER PERMANENTE SPINE

Position Description Ovarian Cancer Australia Support Coordinator, Support Programs

ESPA Directorate KPI Report: Quarter 1,

Teaming Agreement. Grant of Charter and License. Dues. Name and Logo. Mission Commitment. Chapter Standards Compliance.

Alberta s Fire/Search and Rescue Safety Strategy

PARTNERSHIP & SPONSORSHIP OPPORTUNITIES

Good. Poor [ ] [ ] Yes, at all [ A ] Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf [ ] [ ]

Public Health Observatories: An introduction to the London Health Observatory in England and recent developments in Alberta. Learning objectives

OPIOID EMERGENCY RESPONSE REGULATION

London Pathway Evaluation

Alberta Outbreak Response Protocol (AORP) December Government of Alberta

London Pathway Evaluation

Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report of the Advisory Group

Sponsorship Prospectus

Minister s Opioid Emergency Response Commission Recommendations to the Minister Updated July 5, 2018

Call for Applications

INVOLVING YOU. Personal and Public Involvement Strategy

Ontario s Narcotics Strategy

Role Description: Regional Colon Cancer Screening/GI Endoscopy Clinical Lead

Regional variation in health state preferences Does it exist, and does it matter?

BC Confederation of Parent Advisory Councils

BCRTA Awareness Talk

British Sign Language (BSL) College Action Plan

pan-canadian Oncology Drug Review Final Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer February 1, 2018

AND THE COMMUNITY HEALTH PARTNERSHIP INCLUDING THE HEALTH IMPROVEMENT STANDING GROUP. DATE Paper 3.7

KAISER PERMANENTE SPINE

Cancer Control Council Evaluation and Monitoring Framework

Terms of Reference. Tripartite Planning Committee for First Nations & Aboriginal Maternal & Child Health

Dr Richard Harding. King s College London. BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions

Cultural Diversity and Community Advisory Committee Charter July

SALTY Improving End of Life Care in Long Term Care Janice Keefe Scientific Lead and Co Lead Stream 4

July 22, The Smoking Cessation Initiative Description- A Multi-Prong Approach: 1. RNAO Smoking Cessation (SC) Coordinators

Website Briefing document for Multiple Sclerosis Society of Ireland.

Advocacy Strategy

CONSTITUTION SOUTHAMPTON CHILDREN & YOUNG PEOPLE S TRUST PARTNERSHIP

Physicians. Remote. Rural

ALBERTA CLINICAL RESEARCH CONSORTIUM Strategic Plan Phase II STRATEGIC PLAN PHASE II

The Federal Initiative To Address HIV/AIDS in Canada. Canada s Domestic Response to HIV/AIDS

David Patterson The Whittington Hospital, Magdala Avenue, London N19 5NF, UK

The Role of the Medical Director in Long Term Care

Population level Distribution of NRT: Means and Effectiveness from an Ontario wide Study Involving over 25,000 Participants

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

NELFT NHS Foundation Trust About us

Thursday, September 14, 2017 University of Charleston Geary Student Union Building 3rd Floor Ballroom Charleston, WV

2019 Board of Directors Elections Candidate Statement SANDY RENNIE

Evidence-Based Clinical Practice Guideline. Treatment & Management of Ocular Disease

Canadian Health Care Systems

Diabetes Action Now. Consultation on a new WHO-IDF programme

By 20 February 2018 (midnight South African time). Proposals received after the date and time will not be accepted for consideration.

Background. Opportunity. The Proposed Study of e-mh for Youth and Young Adults

Adding Value to the NHS, Health and Care, through Research Management, Support & Leadership

Draft Falls Prevention Strategy

MRC Network of Hubs for Trials Methodology Research Gordon Murray, University of Edinburgh

University of Prince Edward Island PANDEMIC PREPAREDNESS PLAN. October 7, 2009

Dementia Priority Setting Partnership. PROTOCOL March 2012

Regional Clinical Co-Lead (Physician) Role Opportunity

Mesothelioma Outcomes, Research and Experience survey (MORE Survey).

Clinical Pathway Development: Alberta Health Services and Addiction & Mental Health

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Code of Practice on Authorship

Consumer Participation Strategy

IOF TOOLKIT IOF COMPENDIUM OF OSTEOPOROSIS. Our vision is a world without fragility fractures, in which healthy mobility is a reality for all.

Youth Justice National Development Team. Youth Justice National Development Team Annual Report. Fiona Dyer

LEVELS OF NICHE IMPLEMENTATION. Stage 2: Progressive Implementation

Please return the questionnaire in the enclosed pre-paid envelope

Provincial Advisory Council Cancer

POLICY FRAMEWORK FOR DENTAL HYGIENE EDUCATION IN CANADA The Canadian Dental Hygienists Association

Association Agreement

VIOLENCE PREVENTION ALLIANCE TERMS OF REFERENCE

Glen Sather Sports Medicine Clinic Research Strategy

PHYSIOTHERAPY ACT AUTHORIZATION REGULATIONS

Clinical Review Report (Sample)

Interdisciplinary collaborations in research on aging

Transportation and Healthy Aging: Issues and Ideas for an Aging Society

We are currently recruiting new members to advisory groups for the following research programmes:

By 20 February 2018 (midnight South African time). Proposals received after the date and time will not be accepted for consideration.

Distress Screening Playbook

Insight. A message from the Director. In this issue

Transcription:

Alberta PROMs & EQ-5D Research & Support Unit (APERSU): A Brief Introduction Dr. Jeff Johnson January 30, 2016

Faculty/Presenter Disclosure Faculty: Jeff Johnson Relationships with commercial interests: I have no relationships with commercial interests to declare. Relationships with non-commercial interests: I am a member of the Board of Directors for the EuroQol Research Foundation, a not-for-profit organization.

Disclosure of Commercial Support This program has received no financial support. Potential for conflict(s) of interest: No potential conflict of interest; there is no fee to use the EQ-5D instruments by non-commercial organizations, such as PCNs.

Outline About APERSU Vision Agreements & Partnerships Objectives Organizational structure & team Board of Directors Scientific Advisory Committee Services Collaborations & Data Sharing Research Priorities Working with APERSU Why do you want to use the EQ-5D (PROM)? Which EQ-5D instrument (PROM) is best fit for your purpose? How to obtain EQ-5D instruments (registration with the EuroQol Foundation)? How to collect data? (paper-based, web etc ) How to manage data? (database, REDCap, EMR etc..) How to analyze data? How to report/use results?

APERSU Vision To improve decisions by end-users and stakeholders about health and health care in Alberta by promoting, coordinating, and supporting the use of PROMs including the EQ-5D for the measurement and valuation of health.

APERSU Agreements & Partnerships EuroQol Research Foundation HQCA Master Licensing Agreement EQ Foundation & U of A Use of instruments/version Research Agenda Data sharing Sub-licensing to end-users AHS Funding Agreements APERSU Structure BoD, SAC Sub-licensing to end-users Data-sharing Service/Support APERSU SPH, UofA End-user Agreements U of A & non-commercial end-users Data-sharing Service/Support Various Alberta-based End-users

EuroQol Group Established in 1987, the EuroQol Group first met to test the feasibility of jointly developing a standardized, nondisease specific instrument for describing and valuing health-related quality of life. Vision: To improve decisions about health and health care throughout the world by developing, promoting and supporting the use of instruments with the widest possible applicability for the measurement and valuation of health.

EuroQol Group Organizational Structure EQ Group EQ Research Foundation - EQ Research Foundation manages funds from sponsored use of EQ-5D instruments by commercial users, to, in turn, support research and development activities by EQ Group members

APERSU Organizational Structure Board of Directors Scientific Advisory Committee Research Manager Jeffrey A. Johnson, PhD Professor School of Public Health University of Alberta Fatima Al Sayah, PhD Research Associate School of Public Health University of Alberta Co-Directors Research Staff Positions open! (Graduate Students, Post-doctoral Fellows) Arto Ohinmaa, PhD Professor School of Public Health University of Alberta Research Administrator Sherry Lydynuik School of Public Health University of Alberta

APERSU Board of Directors (BoD) Stafford Dean, PhD [chair] Senior Program Officer Analytics Alberta Health Services Charlene McBrien-Morrison Executive Director Health Quality Council of Alberta Tania Bubela, JD, PhD, BSc Professor and Associate Dean (Research) School of Public Health Alberta School of Business University of Alberta A. Simon Pickard, PhD Professor College of Pharmacy University of Illinois at Chicago Executive Committee Chair, EuroQol Research Group Purpose: The Board of Directors (BoD) provides organizational and operational strategic direction to the co-directors, and monitors the performance of APERSU

APERSU Scientific Advisory Committee (SAC) Nancy Devlin, PhD [Chair] Professor Department of Economics, City University, London, UK Director of Research, Institute of Health Economics, UK Gouke J. Bonsel, PhD Professor Urasmus, Netherlands Chair of Large Scale applications working group, EuroQol Foundation Richard Sawatzky, RN, PhD Canada Research Chair in Patient Reported Outcomes, Associate Professor of Nursing Trinity Western University Tim Cooke, PhD Senior Health System Analytical Lead Health Quality Council of Alberta Markus Lahtinen, PhD Measurement Team Lead Health Quality Council of Alberta Brandi McCormack Director, Outcome Measurement & Strategic Initiatives Alberta Health Services Scott Oddie, PhD Director of Measurement and Knowledge Integration, Alberta Health Services Adjunct Associate Professor, Faculty of Social Sciences, Department of Psychology, University of Calgary Deborah Marshall, PhD, MHSA Professor University of Calgary and Arthur J.E. Child Chair of Rheumatology Outcomes Research in the McCaig Institute of Bone and Joint Health Larry Svenson Director, Surveillance and Assessment Branch Alberta Ministry of Health Purpose: The Scientific Advisory Committee (SAC) provides advice and direction to Alberta PROMs & EQ-5D Research & Support Unit (APERSU) Co-Directors regarding APERSU s research agenda and activities

APERSU Objectives 1. Provide expertise, advice and support for the application of the various EQ-5D instruments and other PROMs by provincial endusers, including advice on versions, measurement, scoring and analysis of data collected with the EQ-5D. 2. Provide oversight and coordination of various non-commercial applications of the EQ-5D instruments in Alberta. 3. To register and license all EQ-5D applications under the agreement in Alberta with the Foundation; to serve as a liaison between Alberta-based end-users and the Foundation. 4. Facilitate collaborative research among EQ Group members, and where applicable, with Alberta end-users working with EQ-5D data in the context of large scale health applications.

Objectives (cont d) 5. Develop an innovative research agenda building on the collaboration and end-user agreements in the province, including the novel use of large sets of EQ-5D and PROMs data, as well as testing innovative methods for collection, analysis and use of PROMs data from large-scale health applications in Alberta. 5. Generate information for population health and economic modeling studies to support health policy. 6. Organize an annual research meeting for Albertan, and selected Canadian, EQ-5D end-users to disseminate and share methods, applications and results between stakeholders.

APERSU Services Basic Services Registering and licensing the use of EQ-5D instruments. Providing training, guidance, and support to end-users on the use of PROMs including the EQ-5D. EQ-5D data cleaning and scoring, and report of basic descriptive data analysis. Additional Services Additional support and advice for more advanced analyses such as statistical comparisons, or economic evaluations will be undertaken on a cost recovery basis ($500/day), and would be the based on a separate partnership/funding agreement between the parties.

APERSU Principles of Collaborations 1. Research collaborations are important, and encouraged, between the Foundation, APERSU, Sponsors and various Alberta-based End-users (including Alberta-based sponsors). 2. Many applications of the EQ-5D by End-users, such as in routine outcome measurement and health care delivery planning, will not, by itself, constitute research. 3. Nonetheless, from time-to-time, End-users may be invited to collaborate with APERSU pursuant to an approved research study, which may include sharing limited data elements from their applications of the EQ-5D. 4. These collaborations will be subject to separate data sharing agreements, which shall include provisions that such data, which is contributed to APERSU, must be freely shareable with all Parties. 5. In order to guarantee the coherence of the research endeavors of the Foundation, the Executive Committee of the EuroQol Group will sign off on the structure and content of the research program prior to the start of the first research study. Any changes to the research program must be discussed and agreed with the Executive Committee before deployment. 6. The principal investigator(s) of research studies funded under the APERSU Collaboration Agreement must be a EuroQol Group member based in Alberta. This does not preclude the possibility that researchers (both EuroQol Group members and non-members) based outside Alberta, Canada may participate in these studies.

APERSU Research Priorities Applications of PROMs in clinical practice Applications of PROMs in health systems Understanding the instrument better Enhancing Quality of PROMs Use

Working with APERSU Why do you want to use the EQ-5D (PROM)? Which EQ-5D instrument (PROM) is best fit for your purpose? How to obtain EQ-5D instruments (registration with the EuroQol Foundation)? How to collect data? (paper-based, web etc ) How to manage data? (database, REDCap, EMR etc..) How to analyze data? How to report/use results? PROMs PREMs Canadian Norms Decision aids EQ-5D registration Clinical use Value set

Why do you want to use the EQ-5D (PROM)? Program evaluation Routine outcome measurement Effectiveness of interventions clinical effectiveness Economic evaluation cost-effectiveness Others Important considerations: Population (general, patients, age group, language, etc ) Cross-sectional vs. longitudinal Other data to collect with EQ-5D (or PROM)

Which EQ-5D instrument is better fit for your purpose? EQ-5D-3L Descriptive system: 5 dimensions; 3 levels Visual analogue scale (VAS) EQ-5D-5L Descriptive system: 5 dimensions; 5 levels Visual analogue scale (VAS) EQ-5D-Y Descriptive system: 5 dimensions; 3 levels Visual analogue scale (VAS)

EQ-5D-3L EQ-5D-5L EQ-5D-Y Mobility (walking about) Mobility Self-Care Usual Activities Pain/ Discomfort Anxiety Depression I have no problems in walking I have some problems in walking I am confined to bed I have no problems washing or dressing myself I have some problems washing or dressing myself I am unable to wash or dress myself I have no problems doing my usual activities I have some problems doing my usual activities I am unable to do my usual activities I have no pain or discomfort I have moderate pain or discomfort I have extreme pain or discomfort I am not anxious or depressed I am moderately anxious or depressed I am extremely anxious or depressed I have no problems in walking I have slight problems in walking I have moderate problems in walking I have severe problems in walking I am unable to walk I have no problems washing or dressing myself I have slight problems washing or dressing myself I have moderate problems washing or dressing myself I have severe problems washing or dressing myself I am unable to wash or dress myself I have no problems doing my usual activities I have slight problems doing my usual activities I have moderate problems doing my usual activities I have severe problems doing my usual activities I am unable to do my usual activities I have no pain or discomfort I have slight pain or discomfort I have moderate pain or discomfort I have severe pain or discomfort I have extreme pain or discomfort I am not anxious or depressed I am slightly anxious or depressed I am moderately anxious or depressed I am severely anxious or depressed I am extremely anxious or depressed I have no problems walking about I have some problems walking about I have a lot of problems walking about Looking after myself I have no problems washing or dressing myself I have some problems washing or dressing myself I have a lot of problems washing or dressing myself Doing Usual Activities (for example, going to school, hobbies, sports, playing, doing things with family or friends) I have no problems doing my usual activities I have some problems doing my usual activities I have a lot of problems doing my usual activities Having pain or discomfort I have no pain or discomfort I have some pain or discomfort I have a lot pain or discomfort Feeling worried, sad or unhappy I am not worried, sad or unhappy I am a bit worried, sad or unhappy I am very worried, sad or unhappy 243 health states 3125 health states

How to obtain the EQ-5D? Registration with the EuroQol Foundation End-user license Issued by APERSU Term: 3 years No fees

How to collect data? Modes of data collection: Paper-based Web-based Devices tablets, smartphones Instrument administration: Self-administered Clinician/researcher administered Telephone administered

How to manage data? Develop a database Use EMR or other existing databases Use REDCap Edmonton: https://redcap.med.ualberta.ca/ Calgary: http://cru.ucalgary.ca/services/redcap/

How to analyze data? Dimensions (proportion of individuals reporting problems in each dimension) Index score: Scoring algorithm, interpretation (MID) EQ-VAS

EQ-5D-5L (Descriptive System) Mobility Self-Care Usual Activities Pain/ Discomfort Anxiety Depression I have no problems in walking I have slight problems in walking I have moderate problems in walking I have severe problems in walking I am unable to walk I have no problems washing or dressing myself I have slight problems washing or dressing myself I have moderate problems washing or dressing myself I have severe problems washing or dressing myself I am unable to wash or dress myself I have no problems doing my usual activities I have slight problems doing my usual activities I have moderate problems doing my usual activities I have severe problems doing my usual activities I am unable to do my usual activities I have no pain or discomfort I have slight pain or discomfort I have moderate pain or discomfort I have severe pain or discomfort I have extreme pain or discomfort I am not anxious or depressed I am slightly anxious or depressed I am moderately anxious or depressed I am severely anxious or depressed I am extremely anxious or depressed Levels of perceived problems are coded as follows 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 Level = 2 Level = 1 Level = 1 Level = 3 Level = 4 Health state 21134 Scoring (Canadian Algorithm) Health state 21134 EQ-5D-5L index score = 1.1351-0.0389*MO -0.0458*SC -0.0195*UA -0.0444*PD -0.0376*AD -0.0510*(MO45) -0.0584*(SC45) -0.1103*(UA45) -0.1409*(PD45) -0.1277*(AD45) +0.0085*Num45sq EQ-5D-5L index score = 1.1351-0.0389*2-0.0458*1-0.0195*1-0.0444*3-0.0376*4-0.0510*0-0.0584*0-0.1103*0-0.1409*0-0.1277*1 +0.0085*1 2 = 0.5892

EQ-Visual Analogue Scale (VAS) We would like to know how good or bad your health is TODAY. This scale is numbered from 0 to 100. 100 means the best health you can imagine. 0 means the worst health you can imagine. Mark an X on the scale to indicate how your health is TODAY. Now, please write the number you marked on the scale in the box below. Your Health today = 95 The best health you can imagine The worst health you can imagine 100 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0

How to report/use results? Depends on your: Purpose Audience EQ-5D Data Presence or level of problems by dimension Index score EQ-VAS data

Percentage of respondents by EQ-5D-5L dimension and age group, Alberta (2014) http://hqca.ca/studies-and-reviews/health-outcomes-measurement/

Counts of respondents reporting no problems versus problems by EQ-5D-5L dimension and age group, Alberta (2014) http://hqca.ca/studies-and-reviews/health-outcomes-measurement/

Insert APERSU logo here Percentage of respondents reporting problems by EQ-5D-5L dimension and age, Alberta (2014) http://hqca.ca/studies-and-reviews/health-outcomes-measurement/

Alberta Provincial Norms for EQ-5D-3L; 2013 http://hqca.ca/studies-and-reviews/health-outcomes-measurement/

Histogram of EQ-VAS scores for Alberta, (2014) http://hqca.ca/studies-and-reviews/health-outcomes-measurement/

EQ-5D & QALYs A quality-adjusted life-year (QALY) takes into account both the quantity and quality of life. Simple calculation: (number of years added)*(quality weight) EQ-5D index scores are used to calculate QALYs Healthy = 1.0 State i = 0.65 Dead = 0 0 0.65 X 8 years = 5.2 QALYs 8 Time (yr) QALYs are used in cost-utility analysis Ratio of incremental costs over incremental QALYs cost (A) cost (B) / QALY (A) QALY (B) QALYs provide a common currency to assess the extent of the benefits gained from a variety of interventions in terms of health related quality of life and survival for the patient.

Contact us Located at: 2-040 Li Ka Shing Centre for Health Research Innovation, University of Alberta Email: apersu@ualberta.ca Phone: 780-248-1010 Website: www.apersu.ca coming soon!